<DOC>
	<DOCNO>NCT02034500</DOCNO>
	<brief_summary>This Phase 1 clinical trial aim evaluate safety immunogenicity 3 dos candidate vaccine Shigella sonnei ( 1790GAHB vaccine ) administer different dosage different route ( intradermally , intranasally intramuscularly ) healthy adult ( 18 45 year age enrollment ) . The safety profile 1790GAHB vaccine evaluate comparison placebo ( GAHB-Placebo ) , constitute aluminum hydroxide suspension concentration study vaccine formulation . A total 52 eligible subject assign one three sequential cohort follow : Cohort A ) 0.1 μg ID 5 μg IN Cohort B ) 1 μg ID 20 μg IN Cohort C ) 10 μg ID , 80 μg IN 5 μg IM Within cohort , observer-blind fashion , subject randomize receive three vaccination , four week apart , either 1790GAHB vaccine ( five antigen concentration ) GAHB placebo . Specifically IN ID administration route , Data Safety Monitoring Board place receive summary safety data obtain one week follow-up post-first vaccination lower dose . Based evaluation safety data , Data Safety Monitoring Board make recommendation , whether next cohort vaccinate high antigen concentration . Expected duration study individual subject 9 month . Each subject followed-up 6 month 3rd vaccination</brief_summary>
	<brief_title>Evaluate New Shigella Sonnei Vaccine Administered Either Intradermal , Intranasal Intramuscular Route Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females age ≥18 year ≤45 year . 2 . Individuals , nature study explain , give write consent accord local regulatory requirement . 3 . Individuals good health determine outcome medical history , physical examination , hematology , renal , bone liver panel ( include negative agglutination test S. sonnei ) , urinalysis clinical judgment investigator . 4 . If woman childbearing potential , negative pregnancy test prior study vaccination willingness use acceptable contraceptive measure entire study duration . 5 . Individuals available followup duration study . 6 . Individuals register general practitioner . 1 . Individuals history recurrent wheezing , asthma , respiratory allergy , allergic rhinitis , nasal surgery significant nasal abnormality ( e.g . polyp ) , Bell 's palsy . Presence nasal piercings . Symptoms upper respiratory tract infection within 3 day intend study vaccination temporary exclusion criterion . 2 . Individuals unwilling abstain medication agent apply via nasal route 24 hour prior nasal dose safety assessment 1 week later . 3 . Individuals behavioral cognitive impairment psychiatric disease , opinion investigator , may interfere subject 's ability participate study . 4 . Individuals progressive severe neurological disorder , seizure disorder GuillainBarré syndrome . 5 . Individuals able understand follow require study procedure whole period study . 6 . Individuals history illness , opinion investigator , might interfere result study pose additional risk subject due participation study . 7 . Individuals human leukocyte antigen ( HLA ) B27 positive and/or history reactive arthritis 8 . Individuals know HIV , HBV HCV infection HIV related disease , history autoimmune disorder know suspected impairment /alteration immune system , immunosuppressive therapy include use systemic corticosteroid chronic use inhale highpotency corticosteroid within previous 30 day , chemotherapy treatment within past 6 month . 9 . Individuals know bleed diathesis , condition may associate prolonged bleeding time . 10 . Individuals serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , insulin dependent diabetes , cardiac , renal hepatic disease ) . 11 . Individuals malignancy lymphoproliferative disorder . 12 . Individuals history allergy vaccine component . 13 . Individuals participate clinical trial another investigational product 90 day prior first study visit intent participate another clinical study time conduct study . 14 . Individuals receive vaccine within 4 week prior enrollment study planning receive vaccine within entire study duration except influenza vaccination , allow within period include 4 week 1st vaccination 4 week 3rd vaccination 15 . Individuals receive blood , blood product and/or plasma derivative include parenteral immunoglobulin preparation past 12 week . 16 . Individuals part study personnel close family member personnel conduct study employee clinical trial site institution . 17 . Individuals body temperature &gt; 38.0 degree Celsius within 3 day intend study vaccination . 18 . BMI &gt; 30 kg/m2 . 19 . Individuals history substance alcohol abuse within past 2 year . 20 . Women pregnant breastfeed childbearing age use plan use acceptable birth control measure , duration study . 21 . Females history stillbirth , neonatal loss , previous infant anomaly . 22 . Individuals previously ascertain suspected disease cause S. sonnei positive S. sonnei serology screen 23 . Individuals household contact with/and intimate exposure individual laboratory confirm S. sonnei 24 . Any condition , , opinion investigator may pose increase unreasonable safety risk subject participate present study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>prevention</keyword>
	<keyword>Shigella sonnei</keyword>
</DOC>